[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365987-105":59,"doc-detail-365987-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-roles-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-cip2a-in-ovarian-cancer","Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer","","Ovarian cancer (OvCa) remains a major cause of death and is often diagnosed at advanced stages without effective population screening. This study provides a comprehensive overview of the oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in OvCa using in silico tools, clinical samples, and in vitro models. CIP2A is overexpressed in OvCa, associates with worse overall and progression-free survival, and shows additional mechanistic effects including miRNA/mRNA target interactions and disrupted p53-pathway–related processes following CIP2A inhibition in a BRCA2 model. Functional and transcriptomic evidence also supports biomarker and therapeutic potential, including drug repurposing via CIP2A inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-roles-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-cip2a-in-ovarian-cancer/365987/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-roles-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-cip2a-in-ovarian-cancer/365987.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CIP2A and why is it relevant to ovarian cancer?","Question",{"text":112,"@type":113},"CIP2A is an endogenous inhibitor of protein phosphatase 2A (PP2A) and an oncoprotein. It regulates cellular processes such as proliferation and DNA damage and is implicated in the progression of malignancies, including ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CIP2A expression relate to patient outcomes in ovarian cancer?",{"text":117,"@type":113},"CIP2A is overexpressed in ovarian cancer patients. Higher CIP2A expression is linked to reduced overall survival and progression-free survival, including findings related to metastatic disease.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the potential of targeting CIP2A therapeutically?",{"text":121,"@type":113},"The study uses in vitro inhibition in a BRCA2 model with RNA-sequencing, showing transcriptomic changes enriched in pathways such as p53 signaling, DNA replication, and cell cycle. These results, along with target interaction evidence, support CIP2A as a candidate for therapeutic intervention and drug repurposing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365987,1790895731,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEmerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer  \nAlice Filipe1, Sayeh Saravi1, Denis Mustafov1,2, Suzana Panfilov1, Simran Banger1, Seyedehnajmeh Mousavikivaj1, Maria Braoudaki2, Senthilkumar Kailasam3, Yasser Riazalhosseini3, Michelle A. Sahai1, Fotios Drenos1, Cristina Sisu1 & Emmanouil Karteris1􀀍  \nOvarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of in silico tools, clinical samples and in vitro models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall-and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects ofCIP2A inhibition in an in vitro BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role ofCIP2A in OvCa and the potential of drug repurposing for therapeutic interventions.  \nOvarian cancer (OvCa) is one of the leading causes of death for female patients with gynaecological cancers, responsible for 313,959 cases worldwide annually1. OvCa is an umbrella term for an amalgamation of different ovarian malignancies, each of which presents with distinct features, affecting disease progression2. Due to a lack of effective screening3 as well as vague and confounding symptoms4approximately 70% of patients are diagnosed at the later stages (III or IV)3,4. Currently, no screening program for OvCa exists for the general population. This is because overall, the incidence of the disease is low and false positive screens for OvCa can result in unwanted interventions. Additionally, a screening test must detect OvCa in a state where it is treatable and potentially curable. Current strategies to diagnose OvCa are based primarily on blood tests (e.g. measuring CA-125, HE4) and imaging, both of which have certain limitations5,6.  \nThe tumour suppressor, protein phosphatase 2 A (PP2A), is a serine/threonine phosphatase of vital importance for regulating many processes in the cell, such as cell growth, proliferation and apoptosis7. Cancerous inhibitor of PP2A (CIP2A) is a 90 kDa oncoprotein, encoded by the gene KIAA1524 located at 3q13.138,9. It functions as an endogenous PP2A inhibitor and plays a non-essential role in healthy physiology, since it has minimal expression in healthy tissues. Indeed, its highest expression has been documented in immune, intestinal and sperm cells9; contrary to its upregulation in certain cancers. These findings corroborate data from the GenotypeTissue Expression (GTEx) portal, where very low expression of PP2A is measured in normal tissues including: adipose tissue, brain, breast, cervix, colon, fallopian tubes, heart, kidney, ovary, pancreas, prostate, stomach, uterus, vagina, and whole blood10.  \nThrough inhibition of PP2A, CIP2A drives dysregulation of signalling pathways, since it can interact with other oncoproteins such as MYC, Akt, as well as mTOR to encourage tumour progression11. A number of studies have shown that CIP2A is over-expressed in many cancers including breast12,endometrial13and cervical14. In OvCa, CIP2A has been shown to be over-","cbCaitb68FQPjCvq","https://ap.wps.com/l/cbCaitb68FQPjCvq","pdf",4823777,15,"English","# Results\n## Expression of CIP2A (KIAA1524) in health and gynaecological malignancies","[{\"question\":\"What is CIP2A and why is it relevant to ovarian cancer?\",\"answer\":\"CIP2A is an endogenous inhibitor of protein phosphatase 2A (PP2A) and an oncoprotein. It regulates cellular processes such as proliferation and DNA damage and is implicated in the progression of malignancies, including ovarian cancer.\"},{\"question\":\"How does CIP2A expression relate to patient outcomes in ovarian cancer?\",\"answer\":\"CIP2A is overexpressed in ovarian cancer patients. Higher CIP2A expression is linked to reduced overall survival and progression-free survival, including findings related to metastatic disease.\"},{\"question\":\"What evidence supports the potential of targeting CIP2A therapeutically?\",\"answer\":\"The study uses in vitro inhibition in a BRCA2 model with RNA-sequencing, showing transcriptomic changes enriched in pathways such as p53 signaling, DNA replication, and cell cycle. These results, along with target interaction evidence, support CIP2A as a candidate for therapeutic intervention and drug repurposing.\"}]","Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer | PDF",1790163408,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbb2834cf39622381a7d24efaa819a96.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df83042a1e29dd24f6a47d9504f8c5e3.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a53ac9bbdf8d5d62b1ffd0507a219bab.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8720a1c1c23ca19b1b93d831e2c27af0.webp",980,1287]